Key facts
- The U.S. has launched a Section 301 trade investigation into Germany.
US launches Section 301 probe into Germany over drug pricing
IN SHORT
The U.S. has initiated a Section 301 trade investigation into Germany, alleging the country underpays for innovative medicines. U.S. Trade Representative Jamieson Greer expressed concern over German legislative plans to reduce pharmaceutical spending, warning of potential retaliatory tariffs.
Key Numbers
Section 301Trade Act provision
June 25Docket opening date
$23 billionGerman healthcare funding gap
Who's Involved
United States
Launched Section 301 trade investigation into Germany
Jamieson Greer
U.S. Trade Representative leading the investigation
Germany
Subject of U.S. trade probe over drug pricing plans
German Ministry of Health
Unveiled plans to overhaul healthcare system
↳ Why This Matters
The investigation could lead to punitive tariffs on German imports, impacting trade relations between the two economic powers and potentially affecting the global pharmaceutical market.